Examkin

Soru

Zorluk: ZorRheumatology and Immunology

A 72-year-old man is evaluated on postoperative day 3 following an elective open inguinal hernia repair. He complains of sudden, severe pain and swelling in his right knee that woke him from sleep. His medical history is significant for chronic kidney disease with a baseline serum creatinine of 2.6 mg/dL, and hypertension. His current medications include subcutaneous enoxaparin and oral diltiazem. Temperature is 38.3°C (100.9°F), blood pressure is 142/84 mm Hg, and heart rate is 92/min. Physical examination shows a warm, markedly swollen, and erythematous right knee. Range of motion is severely limited by pain. Laboratory studies show a leukocyte count of 12,500/µL and a serum creatinine of 2.7 mg/dL. Arthrocentesis of the right knee yields 25 mL of turbid yellow fluid. Synovial fluid analysis reveals a leukocyte count of 35,000/µL (85% neutrophils). Polarized light microscopy demonstrates numerous rhomboid-shaped crystals with positive birefringence. Gram stain reveals no organisms. Which of the following is the most appropriate next step in the management of this patient?

  1. A
    Obtain a chest radiograph and blood cultures
  2. B
    Oral indomethacin
  3. Intra-articular triamcinolone injectionCevap
  4. D
    Oral colchicine
  5. E
    Intravenous vancomycin and ceftriaxone

Cevap

Intra-articular triamcinolone injection
The most appropriate next step in management is an intra-articular glucocorticoid injection. This patient is experiencing an acute flare of calcium pyrophosphate deposition (CPPD) disease (pseudogout). This diagnosis is established by the acute monoarticular presentation and the synovial fluid analysis demonstrating an inflammatory effusion with rhomboid-shaped, positively birefringent crystals. First-line therapies for an acute pseudogout flare include NSAIDs, colchicine, and glucocorticoids (systemic or intra-articular). However, this patient's advanced chronic kidney disease (serum creatinine 2.7 mg/dL) strictly contraindicates the use of NSAIDs. Colchicine is also a poor choice due to its reliance on renal clearance and an extremely dangerous drug-drug interaction with diltiazem (a moderate CYP3A4 inhibitor). Concomitant use of colchicine and a CYP3A4 inhibitor in a patient with renal failure strongly risks fatal colchicine toxicity. For acute monoarthritis in a patient with multiple systemic comorbidities and contraindications, an intra-articular glucocorticoid injection (such as triamcinolone) provides targeted, highly effective relief with negligible systemic absorption or renal risk.

Adım Adım Çözüm

1
Diagnose the underlying acute joint pathology using synovial fluid analysis.
The presence of an inflammatory fluid (35,000 leukocytes/µL) with numerous rhomboid-shaped, positively birefringent crystals and a negative Gram stain confirms an acute flare of calcium pyrophosphate deposition (CPPD) disease (pseudogout).
Establishing the correct diagnosis prevents unnecessary empiric therapies, such as antibiotics for septic arthritis.
2
Evaluate standard first-line therapies for acute CPPD arthritis against the patient's comorbidities.
First-line therapies include NSAIDs, colchicine, and systemic or intra-articular glucocorticoids. The patient has stage 4 chronic kidney disease (CKD).
Renal function heavily dictates the safety profile of standard rheumatologic medications.
3
Eliminate contraindicated or highly risky pharmacologic options.
NSAIDs (e.g., indomethacin) are contraindicated in advanced CKD. Colchicine requires severe dose reduction in CKD and is further contraindicated here because the patient takes diltiazem, a CYP3A4 inhibitor that blocks colchicine metabolism, risking fatal toxicity.
Preventing severe iatrogenic harm, including acute-on-chronic renal failure and colchicine toxicity (neuromyopathy, myelosuppression).
4
Select the safest, most effective remaining intervention.
Intra-articular glucocorticoid injection (e.g., triamcinolone) is chosen.
It provides rapid, targeted anti-inflammatory effects for a single joint without significant systemic absorption, bypassing renal and metabolic contraindications.

Anahtar Kavram

For patients with an acute flare of calcium pyrophosphate deposition (CPPD) disease who have severe renal impairment or take interacting medications (e.g., CYP3A4 inhibitors), intra-articular glucocorticoids are the safest and most appropriate initial therapy.
Bu soruyu puanla

Konular

Rheumatology and Immunology

Bu konudan daha fazla soru